Novo Ventures skyder 100 mio kr i nystartet amerikansk biotekselskab

Aristea Therapeutics har sikret sig en stor millionindsprøjtning fra Novo Ventures, der veksler en investering på knap 100 mio. kr. til to bestyrelsesposter i det amerikanske selskab, som er bygget op omkring et middel fra Astrazeneca.
Photo: Novo Holdings/PR
Photo: Novo Holdings/PR

Med Novo Ventures som fødselshjælper har en gruppe amerikanske iværksættere startet virksomheden Aristea Therapeutics, der håber at stå med en mulig behandling mod en uoplyst, alvorlig inflammatorisk sygdom på hånden.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now


Further reading